



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/765,249	01/27/2004	Reiner Fischer	Mo7424D/LeA 34,320	9562
34469	7590 12/01/2005		EXAMINER	
BAYER CROPSCIENCE LP			PRYOR, ALTON NATHANIEL	
Patent Department 100 BAYER ROAD			ART UNIT	PAPER NUMBER
PITTSBURGH, PA 15205-9741			1616	

DATE MAILED: 12/01/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		A	plication No.	Applica	ant(s)				
Office Action Summary		10	0/765,249	FISCHE	FISCHER ET AL.				
		E	caminer	Art Uni	t				
		Al	ton N. Pryor	1616					
Period fo	The MAILING DATE of this communic or Reply	cation appear	s on the cover sheet w	ith the correspon	ndence address				
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAINS IN THE M	AILING DATE of 37 CFR 1.136(a) unication. utory period will ap vill, by statute, caus	OF THIS COMMUNI In no event, however, may a ply and will expire SIX (6) MOI se the application to become A	CATION. reply be timely filed NTHS from the mailing BANDONED (35 U.S.)	date of this communication.				
Status									
1)	Responsive to communication(s) filed	d on <i>27 Janua</i>	ary 2004.						
′=			ion is non-final.		•				
,	,								
,_	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims	·	·						
4)□	Claim(s) 7-15 is/are pending in the ap	oplication.							
•	4a) Of the above claim(s) is/are withdrawn from consideration.								
	5) Claim(s) is/are allowed.								
6)[	Claim(s) 7-15 is/are rejected.								
7)									
8)□	Claim(s) are subject to restricti	ion and/or ele	ection requirement.						
Applicati	on Papers								
9) The specification is objected to by the Examiner.									
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11)	11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	ınder 35 U.S.C. § 119								
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:									
	1.⊠ Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
	application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.									
Attachmen	• •			_					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date									
3) 🔲 Inform	nation Disclosure Statement(s) (PTO-1449 or P r No(s)/Mail Date		5) Notice of I	5) Notice of Informal Patent Application (PTO-152) 6) Other:					

Application/Control Number: 10/765,249

Art Unit: 1616

### **DETAILED ACTION**

#### Election/Restrictions

This application contains claims directed to the following patentably distinct species of the claimed invention: Invention comprising I-b-1 plus numerous (b) compounds.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, an invention comprising I-b-1 plus one or more (b) compounds is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

During a telephone conversation with Attorney R. Henderson on 11/24/05 a provisional election was made with traverse to prosecute the invention of I-b-1 plus diafenthiuron, claims 7-15. Affirmation of this election must be made by applicant in replying to this Office action. Claims 7-15 pertaining to all other combinations of (b) compounds with I-b-1 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 7-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wachendorff-Neumann (WO 2000042850; 07/27/00) and Ruder et al (Pesticide Biochemistry and Physiology, 1991, 41(2), 207-19). US 6706758 is equivalent to WO 2000042850 and will be used as English translation.

Wachendorff-Neumann teaches a composition for controlling insects, comprising an insecticidally effective amount of I-b-1 plus additives such as extenders and surfactants. See

abstract. See abstract, column 1 line 34 – column 2 line 18. Wachendorff-Neumann teaches a method of preparing the composition comprises mixing the active (I-b-1) with surfactants and extenders. See column 2 lines 1-5. Wachendorff-Neumann teaches a method of applying the composition to the insects or their habitats and plants for protection against insects. See claims 1,8. Wachendorff-Neumann does not teach or suggest the invention comprising diafenthiuron. However, Ruder teaches a composition comprising diafenthiuron as a thiourea insecticide/acaricide. Ruder teaches that diafenthiuron functions by inhibiting the mitochondrial respiration by its carbodiimide product. See abstract. In the absence of unexpected results, it would have obvious to one having ordinary skill in the art to have modified the invention of Wachendorff-Neumann to include the diafenthiuron taught by Ruder. One would have been motivated to do this in order to enhance the effectiveness of controlling insect infestation by way of inhibiting mitochondrial respiration.

#### Election Status

The elected invention comprising I-b-1 and diafenthiuron is allowable. See rejection above.

# Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/765,249

**Art Unit: 1616** 

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 5

Alton Pryor

Primary Examiner

AU 1616